Related Experiment Video
Updated: Jul 1, 2026

Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker
Published on: September 15, 2023
PI3K pathway alterations in cancer: variations on a theme.
1Department of Systems Biology, Harvard Medical School and Division of Signal Transduction, Beth Israel Deaconess Medical Center, Boston, MA 2115, USA.
The phosphoinositide 3-kinase (PI3K) pathway is frequently altered in cancer. This review examines PI3K pathway alterations, their oncogenic roles, and tailored treatment strategies for PI3K-addicted tumors.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The phosphoinositide 3-kinase (PI3K) pathway is frequently dysregulated in various cancers.
- PI3K pathway alterations drive tumor growth and present therapeutic targets.
- Numerous PI3K inhibitors are in clinical trials for PI3K-addicted cancers.
Purpose of the Study:
- To re-evaluate the oncogenic mechanisms driven by PI3K pathway alterations.
- To analyze the distinct and redundant roles of genetic alterations in key PI3K pathway nodes.
- To propose targeted treatment strategies based on specific genetic lesions.
Main Methods:
- Review of current literature on PI3K pathway alterations in solid tumors.
- Analysis of oncogenic properties associated with mutations/amplifications in PI3K pathway components.
- Examination of clinical trial data for PI3K inhibitor efficacy.
Main Results:
- Every major node in the PI3K pathway (receptor tyrosine kinases, PI3K subunits, AKT, PTEN) is frequently altered in cancer.
- These alterations contribute to tumorigenesis through various mechanisms.
- PI3K inhibitors show promise in treating cancers with specific PI3K pathway dependencies.
Conclusions:
- Understanding the specific oncogenic roles of PI3K pathway alterations is crucial.
- Tailored treatment strategies based on genetic profiles can optimize therapeutic outcomes.
- Further research is needed to fully elucidate the complexity of PI3K pathway in cancer.
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...